Mid-table players jostle for position as we continue to work our way through Generics Bulletin’s annual Top 50, with mixed fortunes over the past year seeing some companies rise up the rankings as others decline.
After the first part of Generics Bulletin’s annual Top 50 ranking showed how the world’s 10 biggest generics and biosimilars firms had changed position in the past year, that trend has continued into the middle of the pack, as the mixed fortunes of companies occupying positions 11 to 30 have seen some rise up the rankings at the same time as others have slipped down the table.
At the top of our second table we find three major Indian players – Cipla, Dr Reddy’s and Intas –...
This article compiles all of the data from Generics Bulletin’s 2024 ranking of the Top 50 firms across the generics and biosimilars industry, including additional details of how the various financial figures stack up.
In the third instalment of this year’s Generics Bulletin Top 50, we look at some of the firms that have been eliminated from the bottom of our table as others have entered the picture.
In the second part of Generics Bulletin’s Top 50, we see some companies rising up the rankings of generics and biosimilars players worldwide, passing others that are moving in the opposite direction.
Polpharma has struck a deal with MSN Laboratories that will see the Polish generics player distribute the Indian firm’s hospital portfolio in Poland.
Following the FDA’s approval of A 150mg version of Accord’ Herceptin biosimilar, the US agency has now greenlit a higher 400mg strength version of the rival.
